Meta-analysis links many statin side effects to placebo effect

A meta-analysis published in The Lancet in 2026, involving 123,940 participants across 19 clinical studies, suggests that many reported side effects of statins occur at similar rates in both statin and placebo groups.

The study found that 62 out of 66 side effects listed in package inserts—including depression, insomnia, memory impairment, fatigue, and headaches—did not show a significantly increased risk compared to the placebo group. A measurable increase in risk was only confirmed for specific laboratory findings, such as temporarily elevated liver enzymes, protein in urine, and mild edema, occurring in fewer than 1 in 1,000 patients per year.

Researchers emphasized the significant therapeutic benefit of statins, noting that among 10,000 high-risk patients, up to 1,000 severe cardiovascular events like heart attacks or strokes can be prevented over five years. The authors call for an evidence-based revision of package inserts to reduce unnecessary anxiety and prevent the premature discontinuation of essential treatments.